Isoxazoline compounds having mif antagonist activity

Details Isoxazoline compounds having mif antagonist activity Isoxazoline compounds having mif antagonist activity

A - Human Necessities

61

K

A61K 31/42 (2006.01) A61K 31/421 (2006.01) C07D 261/04 (2006.01)

Patent

CA 2450589

Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring system that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatiod arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).

L'invention concerne des procédés d'utilisation de compositions pharmaceutiques pour une genre de composés à faible poids moléculaire comprenant éventuellement des systèmes cycliques d'isoxazoline agissant comme inhibiteurs de MIF (facteur d'inhibition de la migration des macrophages). Plus précisément, les composés permettent de traiter de nombreuses maladies impliquant une activité inflammatoire ou des réactions de cytokine pro-inflammatoires, par exemple des maladies auto-immunes (y compris l'arthrite rhumatoïde, les diabètes insulino-dépendants, la sclérose en plaques, les réactions du greffon contre l'hôte, les syndromes lupiques), l'asthme, l'arthrite, l'insuffisance respiratoire aiguë, le psoriasis, la toxicité de l'interleukine 2, les maladies vasculaires proliférantes et les diverses formes de sepsis et de chocs septiques, et d'autres états pathologiques se caractérisant par des réponses liées au MIF, y compris, par exemple, la croissance tumorale et la néovascularisation (angiogenèse).

Affiliated with

Also associated with

Rating

Isoxazoline compounds having mif antagonist activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Isoxazoline compounds having mif antagonist activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoxazoline compounds having mif antagonist activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2024911